The effect of vitamin D therapy in the improvement of cardiac performance and exercise capacity in patients with heart failure: A double-blind, randomized, placebo-controlled trial

Mohammad Garakyaraghi(1)(2), Mansour Siavash(2)(2), Maryam Kerdegari(3)

Abstract

BACKGROUND: Low vitamin D status may contribute to the pathogenesis of heart failure (HF), but therapeutic roles of vitamin D on cardiac performance are not well known. We evaluated vitamin D effects on left ventricular ejection fraction (LVEF) and New York Heart Association (NYHA) functional class in patients with HF for the first time.

METHODS: This study was a double-blind, randomized, placebo-controlled trial. 110 patients with HF admitted to Shahid Chamran and Khoshid Hospitals, Isfahan, Iran, randomly received 500 mg calcium daily plus either 5000 IU vitamin D3 per week (case group) or placebo (control group) for 6 months. Biochemical variables, LVEF, and NYHA functional class were assessed at baseline and after 6 months.

RESULTS: 81 patients completed the study. Vitamin D supplementation increased mean serum 25-hydroxyvitamin D [25(OH)D] concentration in the case group by 33.9 ng/ml (P < 0.001). After 6 months of treatment, both groups showed improvement in LVEF, but the extent of improvement was significant only in the case group (5.48% versus 0.44%, P < 0.001). The NYHA functional class improved in the case group but remained constant in the control group (P < 0.001).

CONCLUSION: Vitamin D3 improved LVEF and NYHA functional class in patients with HF and might serve as a new agent for the future treatment of this disease.

Keywords: Heart Failure; Vitamin D; Randomized Controlled Trial

Date of submission: 04 Mar. 2020, Date of acceptance: 20 June. 2020

Introduction

Heart failure (HF) is a chronic disease, with worldwide increasing prevalence, especially in elderly people.1-4 Despite recent advances in management, HF so far carries an unacceptably high mortality rate.5,6 Patients with HF, especially elderly people, are prone to nutritional problems.7,8 Reduced mobility may lead to reduced exposure to sunlight and therefore vitamin D synthesis. These patients have considerably lower concentrations of vitamin D metabolites, 25-hydroxyvitamin D [25(OH)D] and its activated form, 1,25-dihydroxyvitamin D [1,25(OH)2D] or calcitriol, than the age-matched healthy controls.9,11

There are several physiologic links between vitamin D and cardiac function. Vitamin D receptor (VDR) exists in a large number of different cell types among them cardiomyocytes, vascular endothelial cells, neurons, and immune cells.10,12,13 Calcitriol is an important regulator of calcium metabolism known as a regulator of intracellular calcium in various tissues and cellular cytokine secretion.10,12,14 Now, calcitriol plays an important role which has been realized recently. In cardiac muscle cells, a calcitriol-dependent calcium (Ca++)-binding protein and calcitriol-mediated rapid activation of voltage-dependent Ca++ channels exist.15,16 This indicates that calcitriol plays a pivotal role in the regulation of myocardial contractility.

How to cite this article: Garakyaraghi M, Siavash M, Kerdegari M. The effect of vitamin D therapy in the improvement of cardiac performance and exercise capacity in patients with heart failure: A double-blind, randomized, placebo-controlled trial. ARYA Atheroscler 2021; 17: 2135.
Additional evidence emphasizing the role of vitamin D deficiency in the pathogenesis of HF comes from the mice, in which VDR was genetically disrupted. Impairment of VDR in these mice resulted in over-stimulation of the renin-angiotensin system (RAS), the elevation of blood pressure, increasing concentrations of the atrial natriuretic peptide (ANP), and cardiac hypertrophy.\textsuperscript{17}

Although low vitamin D status may contribute to the pathogenesis of HF, the effects of vitamin D therapy on cardiac performance are not well known. The aim of the present study was to assess, for the first time, the efficacy of therapeutic doses of vitamin D on left ventricular ejection fraction (LVEF) and New York Heart Association (NYHA) functional class of patients with HF.

### Materials and Methods

**Study design:** This double-blind, randomized, placebo-controlled study was performed from October 2007 until August 2008. The study was registered and approved at the Iranian Registry of Clinical Trials (IRCT138706121181N1). After approval of the study by the Ethics Committee of the Chancellor of Research of Isfahan University of Medical Sciences, Isfahan, Iran, and obtaining written consent, patients with HF referred to cardiology clinic of Shahid Chamran and Khorshid Hospitals in Isfahan for evaluation and management were invited to participate in this study.

**Participants:** This study was performed in Shahid Chamran and Khorshid Hospitals, in 2007-2008. The inclusion criteria were as follows: providing informed written consent, being ambulatory, NYHA functional class ≤ III, and LVEF ≤ 45%. The exclusion criteria were: untreated hypercalcemia, current or recent nephrolithiasis, intake of supplements containing calcium or vitamin D in recent three months, intake of corticosteroids or anticonvulsants, and serum vitamin D in recent three months, intake of supplements containing calcium or vitamin D ≤ 2 mg/dl.

**Interventions:** The intervention group received a pearl containing 50000 IU of vitamin D\textsubscript{3} (Zahravi, Iran) per week and the control group received the placebo (an exactly similar pearl containing olive oil) for six months. Moreover, as the usual dietary calcium intake was less than recommended daily allowance, participants of both groups received a daily supplement of 500 mg calcium carbonate to improve calcium intake and to simplify the evaluation of vitamin D effects independent of calcium.

**Outcomes:** The primary endpoints of the study were LVEF and NYHA functional class. At the baseline visit and at the end of the study, we performed transthoracic echocardiography (TTE) to evaluate LVEF and also obtained blood samples for the assessment of calcium, phosphorus, albumin, 25(OH)D\textsubscript{3}, creatinine, and serum parathyroid hormone (PTH) concentration. We used a Vingmed 800 CF system for TTE and assessed LVEF by Biplane Simpson Method. Exercise capacity was assessed by a questionnaire and reported based on NYHA functional classification.\textsuperscript{18}

We obtained blood samples of the participants from the antecubital vein, after a 12-hour fast. After centrifugation at room temperature for 10 minutes, serum samples were extracted, frozen, and stored at -20°C until analysis.

We measured 25(OH)D\textsubscript{3} by chemiluminescent immunoassay (CLIA) (DiaSorin Inc., Stillwater, MN, USA). The PTH (reference range: 16-65 pg/ml) was measured by radioimmunoassay (RIA) [immunoradiometric assay (IRMA), Immunotech (Beckman Coulter, Czech Republic)]. Serum calcium concentration was assessed by the use of the colorimetric method (Darman Kave, Isfahan, Iran). Albumin, phosphorous, and creatinine were also measured by colorimetric method (Pars Azmun, Karaj, Iran).

**Randomization and blinding:** After obtaining informed consent from the participants, they were randomly (by computer-generated random number lists) assigned to the intervention (case) and control groups. Each patient, depending on the pre-defined group, received a code and all other procedures or evaluations were based on the specified code. Only the final analysis was performed by unmasking the code. Therefore, both the participants and the research group were blinded to the grouping of the patients.

**Statistical methods:** Statistical data were analyzed by SPSS software (version 15, SPSS Inc., Chicago, IL, USA). Categorical variables were presented as number and percentage. They were compared between groups using the chi-square ($\chi^2$) test. Function class was reported as above and was compared between groups using Mann-Whitney test and within groups by Wilcoxon test. The normal distribution of parameters was assessed by Kolmogorov-Smirnov test (K-S test). LVEF and other parametric variables were presented as mean ± standard deviation (SD). These variables and the extent of their changes from baseline were compared between groups using student’s t-test and within groups (before and after treatment) by paired t-test.
Results

Baseline data: 110 patients with HF (77 men and 33 women) entered the study, 81 patients completed the study (39 in the case and 42 in the control groups). The baseline characteristics of the participants are presented in Table 1. There was no significant difference regarding baseline characteristics between the two groups. 10 patients from the case group and 8 patients from the control group did not complete the study. 5 patients died during the study and until two more following months (2 in the control and 3 in the case groups). There was no significant difference in the survival rate in the case and the control groups (95.6% and 97.0%, respectively, P = 0.673). 3 patients could not complete the study because of deterioration in the health status (one patient developed pulmonary thromboembolism (PTE), one patient because of stroke, and the other one had decompensated HF). 3 patients were excluded from the study, because they needed invasive interventional treatments for ischemic heart disease (IHD) (one patient underwent coronary bypass surgery and two of them received coronary stent). Figure 1 shows a Consolidated Standards of Reporting Trials (CONSORT) flowchart of the study process.

Outcomes: Baseline 25(OH)D₃ concentration in both groups was in the range of hypovitaminosis D. The prevalence of low vitamin D status in participants was 83.6% (85.3% in controls vs. 81.8% in the case group, P = 0.700). The mean serum vitamin D₃ concentration was 22.7 ± 21.1 ng/ml. At the end of the study, there was a significant elevation of serum concentration of 25(OH)D₃ in the case group (22.85 ± 19.97 versus 55.40 ± 31.53 ng/ml, P < 0.001). In the control group, 25(OH)D₃ increased from 22.46 ± 22.28 to 29.17 ± 19.76 ng/ml (P = 0.120).

After 6 months of intervention, both groups showed improvement in LVEF that only was significant in the case group (Table 2). The extent of changes between the two groups was significantly different (P < 0.001) (Figure 2). 52% of the participants in the case group versus 7% in the control group improved in NYHA functional class.

The mean serum albumin increased significantly in both groups (0.26 g/dl in the case group, P < 0.001; and 0.120 g/dl in the control group, P = 0.010). Serum PTH did not change significantly in both groups (P < 0.050). We followed the participants until 2 years after the study with a recommendation for adequate calcium and vitamin D supplementation. There was no significant difference in mortality in two groups (3 in the case versus 2 in the control group, P = 0.500).

Discussion

Our study showed that weekly 50000 IU vitamin D supplementation for six months improved NYHA functional class and LVEF of patients with HF. This improvement was independent of supplementary calcium intake. We also observed a significant improvement in the left ventricular end-systolic volume (LVESV) that has been an independent predictor of survival in patients with low ejection fraction (EF). Other studies have shown positive effects of vitamin D in HF.

Table 1. Baseline characteristics of the participants

| Characteristics | Study group (n = 39) | Placebo group (n = 42) | P* |
|-----------------|----------------------|-----------------------|----|
| Gender (men)    | 28 (71.8)            | 29 (69.0)             | 0.787 |
| Cigarette smoking |                     |                       |     |
| Current         | 8 (20.5)             | 5 (11.9)              | 0.554 |
| Past            | 2 (5.1)              | 3 (7.1)               |     |
| CAD             | 26 (66.6)            | 20 (47.6)             | 0.120 |
| HTN             | 23 (59.0)            | 31 (73.8)             | 0.160 |
| Diabetes        | 10 (25.6)            | 12 (28.6)             | 0.767 |
| NYHA            |                      |                       | 0.295 |
| I               | 3 (7.7)              | 6 (14.3)              |     |
| II              | 27 (69.3)            | 29 (69.0)             |     |
| III             | 9 (23.0)             | 7 (16.7)              |     |
| Age (year)      | 59.46 ± 10.90        | 61.93 ± 10.80         | 0.316 |
| LVEF (%)        | 31.20 ± 7.78         | 32.32 ± 5.81          | 0.436 |
| LVESV (mm³)     | 135.38 ± 75.42       | 110.11 ± 42.79        | 0.070 |

Data are presented as mean ± standard deviation (SD) or number and percentage

* Independent t-test or chi-square test, as appropriate

CAD: Coronary artery disease; HTN: Hypertension; NYHA: New York Heart Association; LVEF: Left ventricular ejection fraction; LVESV: Left ventricular end-systolic volume
Figure 1. The study flow diagram based on Consolidated Standards of Reporting Trials (CONSORT)
PTE: Pulmonary thromboembolism; CABG: Coronary artery bypass graft; PCI: Percutaneous Coronary Intervention; HF: Heart failure

The possible mechanisms underlying the beneficial effects of vitamin D on myocardial function and HF may be related to its role in regulation of inflammation, inhibition of myocardial cell hypertrophy and fibrosis and adverse remodeling, regulation of rennin-angiotensin-aldosterone system (RAAS), metabolic effects of vitamin D on the cardiac muscle by affecting calcium, phosphorus, or other components of muscle contraction, improvement of secondary hyperparathyroidism, which has been shown as a contributing factor to cardiac muscle dysfunction, and direct effects of vitamin D, independent of calcium, phosphorus, or parathyroid.

Table 2. The studied variables and changes from the baseline

| Variable             | Baseline       | Change from baseline | P (for changes between groups) |
|----------------------|----------------|-----------------------|--------------------------------|
|                      | Case group     | Control group         | Case group                     | Control group |                       |
| 25(OH)D (ng/ml)      | 25.85 ± 19.97  | 22.46 ± 22.28         | 0.940                          | 33.91 ± 31.03 | 6.21 ± 22.03           | < 0.001                 |
| Calcium (mg/dl)      | 9.58 ± 0.54    | 9.43 ± 0.56           | 0.240                          | 0.09 ± 0.74   | 0.24 ± 0.73            | 0.410                   |
| PTH (pg/ml)          | 33.03 ± 18.21  | 32.70 ± 22.22         | 0.960                          | 0.83 ± 29.03  | 1.92 ± 22.93           | 0.870                   |
| Phosphate (mg/dl)    | 3.62 ± 0.58    | 3.65 ± 0.43           | 0.820                          | 0.17 ± 0.61   | 0.14 ± 0.58            | 0.820                   |
| Creatinine (mg/dl)   | 1.11 ± 0.26    | 1.06 ± 0.29           | 0.510                          | -0.13 ± 0.17  | -0.06 ± 0.19           | 0.130                   |
| Albumin (g/dl)       | 4.05 ± 0.28    | 4.03 ± 0.19           | 0.740                          | 0.26 ± 0.37   | 0.11 ± 0.23            | 0.050                   |
| LVEF (%)             | 31.20 ± 7.78   | 32.32 ± 5.81          | 0.436                          | 5.48 ± 4.46   | 0.44 ± 5.62            | < 0.001                 |
| LVES (mm²)           | 135.27 ± 72.75 | 109.90 ± 43.08        | 0.070                          | -27.92 ± 65.66| -3.11 ± 17.54         | 0.020                   |
| NYHA functional class| 2.15 ± 0.54    | 2.02 ± 0.56           | 0.300                          | -0.51 ± 0.51  | -0.05 ± 0.40           | < 0.001                 |

All values are shown as mean ± standard deviation (SD)
* **: Independent t-test or Mann-Whitney test, as appropriate; * Change is significantly different from baseline within a subgroup (paired t-test)

PTH: Parathyroid hormone; LVEF: Left ventricular ejection fraction; LVES: Left ventricular end-systolic; NYHA: New York Heart Association
Inflammatory cytokine [tumor necrosis factor alpha (TNF-α)] decreases and anti-inflammatory cytokine [interleukin-10 (IL-10)] increases after 9 months of treatment by vitamin D in patients with HF in comparison to the control group. Vitamin D3 reduces the inflammatory milieu in patients with HF and might serve as a new anti-inflammatory agent for the treatment of the disease. Active vitamin D (calcitriol) has anti-proliferating capability and might reduce myocardial hypertrophy and fibrosis. Calcitriol has also a negative endocrine effect on the RAAS. Activated 1,25(OH)2D3 suppresses renin gene transcription by blocking the activity of the cyclic adenosine monophosphate (cAMP) response element in the renin gene promoter and inhibits renin secretion from the juxtaglomerular apparatus. By reducing plasma rennin activity, it reduces angiotensin II levels and so, blood pressure.

Most patients with HF in this study were in the stage of hypovitaminosis D (22.7 ± 21.1 ng/ml). Other studies have also shown that patients with HF had mean serum concentrations around or below 20 ng/ml, i.e., in the insufficiency or even deficiency range. The prevalence of low vitamin D status in cardiovascular disease (CVD) recently was reported 74% overall. Our results are consistent with other studies regarding the beneficial effects of vitamin D supplementation on exercise capacity, functional class, and left ventricular (LV) function in patients with HF.

In some earlier animal and human studies, vitamin D deficiency rickets has been associated with HF and its supplementation has improved the condition. Abdullah et al. introduced a five-month-old boy with severe dilated cardiomyopathy (DCM) with hypocalcemia due to vitamin D deficiency rickets. His cardiac function recovered completely after six months of vitamin D supplementation. Amirlak et al. also reported two 9-month-old breastfed infants with congestive HF (CHF) secondary to DCM and advanced rickets. Following treatment with vitamin D and calcium supplements, both infants quickly recovered normal myocardial function. Multiple similar reports of infants are present in the literature. Alsafwah et al. reported that hypovitaminosis D was a contributory factor in decompensated HF in African Americans residing in Memphis, Tennessee, United States (US). Pilz et al. also reported that low levels of 25(OH)D and 1,25(OH)2D were associated with prevalent myocardial dysfunction, deaths due to HF, and sudden cardiac death. They recommended interventional trials to elucidate the role of vitamin D supplementation for treatment or prevention of myocardial diseases.

We observed some improvement in LVEF in the control group. As the NYHA functional class of these patients did not differ from baseline, it may indicate that the improvement of LVEF in the control group does not have a clinical value. At the end of the study, the biochemical parameters such as calcium, phosphorus, and PTH did not change significantly from the baseline. As patients with impairments of PTH-calcium axis were excluded from the study, and also participants of both groups received supplemental calcium, it seems that vitamin D benefits are unrelated to this axis and may confirm previous animal studies regarding its direct effects on the cardiac muscle.

At the end of the study, serum albumin concentrations increased in both groups. This finding may be due to the close observation of these patients and improvement in health care of them during the study period and may be the effect of improvement on microalbuminuria in these patients. Our study had some limitations. First, the small number of participants may limit recommending its use as a general recommendation. Second, the
duration of the study follow-up is not very prolonged, so judgment about survival benefits of vitamin D is not possible. The patients should be followed up for a more prolonged duration to assess the influence of this intervention on the survival rate.

**Conclusion**

Treatment with vitamin D3 improved LVEF and exercise capacity/NYHA functional class in patients with HF and might serve as a complementary agent for the future treatment of this disease.

**Acknowledgments**

The authors want to thank Behnam Rezaci and Parisa Ferdowsi for their kind help to this research and the patients that participated in the study. The study was supported by the Deputy of Research, Isfahan University of Medical Sciences. The present article is the result of a residency research project (No. 387019) with ethics code of ir.mui.rec.1387.3.019 in Isfahan University of Medical Sciences.

**Conflict of Interests**

Authors have no conflict of interests.

**References**

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348(20): 2007-18.
2. Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 2006; 113(6): 799-805.
3. Curtis LH, Whelan DJ, Hammill BG, Hernandez AF, Anstrom KJ, Shea AM, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med 2008; 168(4): 418-24.
4. Forman DE, Ahmed A, Fleg JL. Heart failure in very old adults. Curr Heart Fail Rep 2013; 10(4): 387-400.
5. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: Prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004; 25(18): 1614-9.
6. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008; 101(7): 1016-22.
7. Witte KK, Clark AL, Cleland JG. Chronic heart failure and micronutrients. J Am Coll Cardiol 2001; 37(7): 1765-74.
8. Witte KK, Nikitin NP, Parker AC, von HS, Volk HD, Anker SD, et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 2005; 26(21): 2238-44.
9. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41(1): 105-12.
10. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D insufficiency in congestive heart failure: why and what to do about it? Heart Fail Rev 2006; 11(1): 25-33.
11. Garakrayaghi M, Kerdegari M, Siavash M. Calcium and vitamin D status in heart failure patients in Isfahan, Iran. Biol Trace Elem Res 2010; 135(1-3): 67-73.
12. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006; 92(1): 39-48.
13. Weber KT, Simpson RU, Carbone LD. Vitamin D and calcium dyshomoeostasis-associated heart failure. Heart 2008; 94(5): 540-1.
14. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005; 94(4): 483-92.
15. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992; 85(3): 1046-55.
16. De Boland AR, Boland RL. Non-genomic signal transduction pathway of vitamin D in muscle. Cell Signal 1994; 6(7): 717-24.
17. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288(1): E125-E132.
18. Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. Boston, MA: Little, Brown; 1994.
19. Saadi HF, Kazzam E, Ghurbana BA, Nicholls MG. Hypothesis: Correction of low vitamin D status among Arab women will prevent heart failure and improve cardiac function in established heart failure. Eur J Heart Fail 2006; 8(7): 694-6.
20. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76(1): 44-51.
21. Majeed Babar MZ, Haider SS, Mustafa G. Effects of Vitamin D supplementation on physical activity of patients with Heart Failure. Pak J Med Sci 2016; 32(6): 1430-3.
22. Witte KK, Byrom R, Gierula J, Paton MF, Jamil...
HA, Lowry JE, et al. Effects of vitamin D on cardiac function in patients with chronic HF: The VINDICATE Study. J Am Coll Cardiol 2016; 67(22): 2593-603.
23. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83(4): 754-9.
24. Vieth R,Kimball S. Vitamin D in congestive heart failure. Am J Clin Nutr 2006; 83(4): 731-2.
25. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103(3-5): 521-4.
26. Weber KT, Weglicki WB, Simpson RU. Macronutrient and micronutrient dyshomeostasis in the adverse structural remodelling of myocardium. Cardiovasc Res 2009; 81(3): 500-8.
27. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89-90(1-5): 387-92.
28. Maiya S, Sullivan I, Allgrove J, Yates R, Malone M, Brain C, et al. Hypocalcaemia and vitamin D deficiency: An important, but preventable, cause of life-threatening infant heart failure. Heart 2008; 94(5): 581-4.
29. Witte KK, Clark AL. Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives. Heart Fail Rev 2006; 11(1): 65-74.
30. Weishaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. Am J Physiol 1987; 253(6 Pt 1): E675-E683.
31. Mancuso P, Rahman A, Hershey SD, Andu L, Nibbelink KA, Simpson RU. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+ ) rats independent of changes in serum leptin. J Cardiovasc Pharmacol 2008; 51(6): 559-64.
32. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007: 282(41): 29821-30.
33. Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 2008; 102(11): 1540-4.
34. McGonigle RJ, Fowler MB, Timmis AB, Weston MJ, Parsons V. Uremic cardiomyopathy: Potential role of vitamin D and parathyroid hormone. Nephron 1984; 36(2): 94-100.
35. Price DI, Stanford LC, Braden DS, Ebeid MR, Smith JC. Hypocalcemic rickets: An unusual cause of dilated cardiomyopathy. Pediatr Cardiol 2003; 24(5): 510-2.
36. Abdullah M,Bigas JL, McRindle BW. Dilated cardiomyopathy as a first sign of nutritional vitamin D deficiency rickets in infancy. Can J Cardiol 1999; 15(6): 699-701.
37. AmirI A, Al DW; Narchi H. Dilated cardiomyopathy secondary to nutritional rickets. Ann Trop Paediatr 2008; 28(3): 227-30.
38. Gillor A, Groneck P, Kaiser J, Schmitz-Stolbrink A. Congestive heart failure in rickets caused by vitamin D deficiency. Monatsschr Kinderheilkd 1989; 137(2): 108-10.
39. Brunvand L, Haga P, Tangsrud SE, Haug E. Congestive heart failure caused by vitamin D deficiency? Acta Paediatr 1995; 84(1): 106-8.
40. Olgun H, Ceviz N, Ozkan B. A case of dilated cardiomyopathy due to nutritional vitamin D deficiency rickets. Turk J Pediatr 2003; 45(2): 152-4.
41. Alsafwah S, Laguardia SP, Nelson MD, Battin DL, Newman KP, Carbome LD, et al. Hypovitaminosis D in African Americans residing in Memphis, Tennessee with and without heart failure. Am J Med Sci 2008; 335(4): 292-7.
42. Pilz S, Marz W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP, et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008; 93(10): 3927-35.
43. Michie C, Julies P. Treatments for heart failure in pregnancy: Is it time to consider vitamin D? Int J Clin Pract 2012; 66(3): 328.